OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
Jennifer DeCuir, Amanda B. Payne, Wesley H. Self, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 8, pp. 180-188
Open Access | Times Cited: 44
Jennifer DeCuir, Amanda B. Payne, Wesley H. Self, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 8, pp. 180-188
Open Access | Times Cited: 44
Showing 1-25 of 44 citing articles:
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023–2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach
Ryan E. Wiegand, Owen Devine, Megan J. Wallace, et al.
Vaccine (2025) Vol. 49, pp. 126808-126808
Closed Access | Times Cited: 1
Ryan E. Wiegand, Owen Devine, Megan J. Wallace, et al.
Vaccine (2025) Vol. 49, pp. 126808-126808
Closed Access | Times Cited: 1
Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Hospitalization Among Adults Aged ≥18 Years with Immunocompromising Conditions — VISION Network, September 2023–February 2024
Ruth Link‐Gelles, Elizabeth Rowley, Malini B. DeSilva, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 12, pp. 271-276
Open Access | Times Cited: 13
Ruth Link‐Gelles, Elizabeth Rowley, Malini B. DeSilva, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 12, pp. 271-276
Open Access | Times Cited: 13
Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System
Aisling R. Caffrey, Haley J. Appaneal, Vrishali V. Lopes, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 9
Aisling R. Caffrey, Haley J. Appaneal, Vrishali V. Lopes, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 9
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, October 18, 2023–March 9, 2024
C. Kevin, Diya Surie, Adam S. Lauring, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 9
C. Kevin, Diya Surie, Adam S. Lauring, et al.
Clinical Infectious Diseases (2024)
Open Access | Times Cited: 9
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis
Hagit Kopel, Andre B. Araujo, Alina Bogdanov, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Hagit Kopel, Andre B. Araujo, Alina Bogdanov, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial
Juleen Gayed, Vishva Bangad, Xia Xu, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 734-734
Open Access | Times Cited: 5
Juleen Gayed, Vishva Bangad, Xia Xu, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 734-734
Open Access | Times Cited: 5
Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages — United States, May 2023–September 2024
C. Kevin, Juan E. De Castro, Anastasia S. Lambrou, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 42, pp. 938-945
Open Access | Times Cited: 5
C. Kevin, Juan E. De Castro, Anastasia S. Lambrou, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 42, pp. 938-945
Open Access | Times Cited: 5
Optimizing Missouri's Preparation for the Next Pandemic: Lessons Learned from COVID-19: Part 2.
David S. McKinsey, Joel P. McKinsey, Julie R McKinsey, et al.
PubMed (2025) Vol. 122, Iss. 1, pp. 12-18
Closed Access
David S. McKinsey, Joel P. McKinsey, Julie R McKinsey, et al.
PubMed (2025) Vol. 122, Iss. 1, pp. 12-18
Closed Access
A framework for monitoring RSV prevention product effectiveness in the United States
Lauren E. Roper, Ruth Link‐Gelles, Diya Surie, et al.
Vaccine (2025) Vol. 45, pp. 126633-126633
Closed Access
Lauren E. Roper, Ruth Link‐Gelles, Diya Surie, et al.
Vaccine (2025) Vol. 45, pp. 126633-126633
Closed Access
Adult vaccinations against respiratory infections
Antoní Torres, Catia Cillóniz, Marta Aldea, et al.
Expert Review of Anti-infective Therapy (2025)
Closed Access
Antoní Torres, Catia Cillóniz, Marta Aldea, et al.
Expert Review of Anti-infective Therapy (2025)
Closed Access
Effectiveness of the 2023-to-2024 XBB.1.5 COVID-19 Vaccines Over Long-Term Follow-up
George N. Ioannou, Kristin Berry, Nallakkandi Rajeevan, et al.
Annals of Internal Medicine (2025)
Closed Access
George N. Ioannou, Kristin Berry, Nallakkandi Rajeevan, et al.
Annals of Internal Medicine (2025)
Closed Access
Are Updated COVID-19 Vaccines Still Relevant for all Adult Age Groups? An Economic Evaluation of the Monovalent XBB.1.5 Vaccine in Australia.
Charles Okafor, Syed Afroz Keramat, Namal N. Balasooriya, et al.
Value in Health (2025)
Closed Access
Charles Okafor, Syed Afroz Keramat, Namal N. Balasooriya, et al.
Value in Health (2025)
Closed Access
XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants
Matthew E. Levy, Vanessa Chilunda, Phillip Heaton, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Matthew E. Levy, Vanessa Chilunda, Phillip Heaton, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Update on Vaccination Recommendations for Adults with HIV
Fiona Gispen, Kristen Marks
Current HIV/AIDS Reports (2025) Vol. 22, Iss. 1
Closed Access
Fiona Gispen, Kristen Marks
Current HIV/AIDS Reports (2025) Vol. 22, Iss. 1
Closed Access
Effectiveness of BNT162b2 XBB.1.5 vaccine in immunocompetent adults using tokenization in two U.S. states
Kathleen M. Andersen, Kristen E. Allen, Rajeev M. Nepal, et al.
Vaccine (2025) Vol. 52, pp. 126881-126881
Open Access
Kathleen M. Andersen, Kristen E. Allen, Rajeev M. Nepal, et al.
Vaccine (2025) Vol. 52, pp. 126881-126881
Open Access
Interim Estimates of 2024–2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years — VISION and IVY Networks, September 2024–January 2025
Ruth Link‐Gelles, Sean Chickery, A Webber, et al.
MMWR Morbidity and Mortality Weekly Report (2025) Vol. 74, Iss. 6, pp. 73-82
Open Access
Ruth Link‐Gelles, Sean Chickery, A Webber, et al.
MMWR Morbidity and Mortality Weekly Report (2025) Vol. 74, Iss. 6, pp. 73-82
Open Access
Next-Generation Coronavirus Disease 2019 Vaccines
Kathryn E. Stephenson
Infectious Disease Clinics of North America (2025)
Closed Access
Kathryn E. Stephenson
Infectious Disease Clinics of North America (2025)
Closed Access
Evaluating Humoral Immunity Elicited by XBB.1.5 Monovalent COVID-19 Vaccine
Xammy Nguyenla, Timothy A. Bates, Mila Trank-Greene, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 6
Open Access | Times Cited: 4
Xammy Nguyenla, Timothy A. Bates, Mila Trank-Greene, et al.
Emerging infectious diseases (2024) Vol. 30, Iss. 6
Open Access | Times Cited: 4
Navigating the Evolving Landscape of COVID-19: Strategies to Increase Vaccine Confidence and Improve Vaccination Rates in the United States
James A. Mansi, Heather R. Hensler, Rachel Dawson, et al.
(2024)
Open Access | Times Cited: 4
James A. Mansi, Heather R. Hensler, Rachel Dawson, et al.
(2024)
Open Access | Times Cited: 4
COVID-19–Associated Hospitalizations Among U.S. Adults Aged ≥18 Years — COVID-NET, 12 States, October 2023–April 2024
Christopher A. Taylor, Kadam Patel, Huong Pham, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 39, pp. 869-875
Open Access | Times Cited: 4
Christopher A. Taylor, Kadam Patel, Huong Pham, et al.
MMWR Morbidity and Mortality Weekly Report (2024) Vol. 73, Iss. 39, pp. 869-875
Open Access | Times Cited: 4
Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System
Aisling R. Caffrey, Haley J. Appaneal, Vrishali V. Lopes, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Aisling R. Caffrey, Haley J. Appaneal, Vrishali V. Lopes, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
XBB.1.5 mRNA COVID-19 Vaccination and Inpatient or Emergency Department Visits Among Adults Infected with SARS-CoV-2 JN.1 and XBB-Lineage Variants
Matthew E. Levy, Vanessa Chilunda, Phillip Heaton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Matthew E. Levy, Vanessa Chilunda, Phillip Heaton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine Against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial <strong> </strong>
Juleen Gayed, Vishva Bangad, Xia Xu, et al.
(2024)
Open Access | Times Cited: 2
Juleen Gayed, Vishva Bangad, Xia Xu, et al.
(2024)
Open Access | Times Cited: 2
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
Rohan Ameratunga, A. M. Jordan, Klaus Lehnert, et al.
Antiviral Research (2024) Vol. 227, pp. 105894-105894
Closed Access | Times Cited: 2
Rohan Ameratunga, A. M. Jordan, Klaus Lehnert, et al.
Antiviral Research (2024) Vol. 227, pp. 105894-105894
Closed Access | Times Cited: 2
Early COVID‐19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023–January 2024
Liliana Antunes, Clara Mazagatos, Iván Martínez‐Baz, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 8
Open Access | Times Cited: 2
Liliana Antunes, Clara Mazagatos, Iván Martínez‐Baz, et al.
Influenza and Other Respiratory Viruses (2024) Vol. 18, Iss. 8
Open Access | Times Cited: 2
